ArticleThe Journal of experimental medicine2018
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 59 citations in OpenAlex.
- UBQLN2 links proteotoxicity with lipid metabolism in neurodegeneration.Nature neuroscience · 2026Article
- Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.Blood advances · 2026Article
- Review
- Omics integration identified CRIP2 as a key mediator of olaparib resistance in prostate cancer.Translational andrology and urology · 2025Article
- An orally administered gene editing nanoparticle boosts chemo-immunotherapy in colorectal cancer.Nature nanotechnology · 2025Article
- Role of stem-like cells in chemotherapy resistance and relapse in pediatric T-cell acute lymphoblastic leukemia.Nature communications · 2025Article
- Concurrent Bone Marrow Acute Undifferentiated Leukemia and Mediastinal T-Lymphoblastic Lymphoma With IdenticalEJHaem · 2025Article
- Cysteine-rich intestinal protein family: structural overview, functional diversity, and roles in human disease.Cell death discovery · 2025Review
- Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance.Functional & integrative genomics · 2025Review
- Conventional chemotherapy: millions of cures, unresolved therapeutic index.Nature reviews. Cancer · 2025Review
- BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis.Blood neoplasia · 2024Article
- Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges.The Journal of clinical investigation · 2024Review
- Pancancer analysis of NDUFA4L2 with focused role in tumor progression and metastasis of colon adenocarcinoma.Medical oncology (Northwood, London, England) · 2024Article
- Histone methylation in Epstein-Barr virus-associated diseases.Epigenomics · 2024Review
- GSK3α Regulates Temporally Dynamic Changes in Ribosomal Proteins upon Amino Acid Starvation in Cancer Cells.International journal of molecular sciences · 2023Article
- SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters.Cancers · 2023Article
- PP2A methylesterase PME-1 suppresses anoikis and is associated with therapy relapse of PTEN-deficient prostate cancers.Molecular oncology · 2023Article
- Review
- Polycomb Repressive Complex 2 in Oncology.Cancer treatment and research · 2023Article
- Single-cell sequencing reveals activation of core transcription factors in PRC2-deficient malignant peripheral nerve sheath tumor.Cell reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 11 institutions in 4 countries.
Ingrid M AriësDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Kimberly BodaarDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Salmaan A KarimDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Triona Ni ChonghaileDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Laura HinzeDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Melissa A BurnsDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Maren PfirrmannDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
James DegarDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-5387-9069
Jack T LandriganDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0001-6530-7829
Sebastian BalbachDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Sofie PeirsCenter for Medical Genetics, Ghent University, Ghent, Belgium.ORCID 0000-0001-7036-1053
Björn MentenCenter for Medical Genetics, Ghent University, Ghent, Belgium.ORCID 0000-0001-8182-659X
Randi IsenhartDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Kristen E StevensonDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
Donna S NeubergDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-2566-3145
Meenakshi DevidasDepartment of Biostatistics, University of Florida, Gainesville, FL.
Mignon L LohDepartment of Pediatrics, University of California San Francisco, San Francisco, CA.
Stephen P HungerDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA.
David T TeacheyDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA.
Karen R RabinDivision of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX.ORCID 0000-0002-4081-8195
Stuart S WinterCancer and Blood Disorders Department, Children's Minnesota, Minneapolis, MN.
Kimberly P DunsmoreDepartment of Pediatrics, Carilion Children's, Roanoke, VA.ORCID 0000-0002-6631-5174
Brent L WoodDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Lewis B SilvermanDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Stephen E SallanDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Pieter Van VlierbergheCenter for Medical Genetics, Ghent University, Ghent, Belgium.ORCID 0000-0001-9063-7205
Stuart H OrkinDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-3523-7687
Birgit KnoechelDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Anthony G LetaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Alejandro GutierrezDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA alejandro.gutierrez@childrens.harvard.edu.ORCID 0000-0002-0249-9007
Boston Children's Hospital · USGhent University Hospital · BEHarvard University · USChildren's Hospital of Philadelphia · USDana-Farber Cancer Institute · USBaylor College of Medicine · USCarilion Clinic · USChildren’s Minnesota - St. Paul Hospital · USUniversity of California, San Francisco · USUniversity of Florida · USUniversity of Washington · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MCOG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MChildren's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5MSupport for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5MDiscovery and targeting of apoptosis resistance mechanisms in high-risk T-ALLR01CA193651 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GUTIERREZ, ALEJANDRO · 2015 to 2024
$4.4MEpigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemiaK08CA191091 · NCI · DANA-FARBER CANCER INST · PI KNOECHEL, BIRGIT · 2015 to 2019
$886kDiscovery and Targeting of Apoptosis Resistance Mechanisms in High-Risk T-ALLR21CA167124 · NCI · BOSTON CHILDREN'S HOSPITAL · PI GUTIERREZ, ALEJANDRO · 2012 to 2013
$403kNCI NIH HHS K08 CA191091NCI NIH HHS R01 CA193651NCI NIH HHS R21 CA167124NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114766
Abstract
The tendency of mitochondria to undergo or resist BCL2-controlled apoptosis (so-called mitochondrial priming) is a powerful predictor of response to cytotoxic chemotherapy. Fully exploiting this finding will require unraveling the molecular genetics underlying phenotypic variability in mitochondrial priming. Here, we report that mitochondrial apoptosis resistance in T cell acute lymphoblastic leukemia (T-ALL) is mediated by inactivation of polycomb repressive complex 2 (PRC2). In T-ALL clinical specimens, loss-of-function mutations of PRC2 core components (
Indexed as
ApoptosisDrug Resistance, NeoplasmAntineoplastic AgentsCell Line, TumorFemaleGene Expression Regulation, LeukemicHumansMaleMitochondriaNeoplasm ProteinsPolycomb Repressive Complex 2Precursor T-Cell Lymphoblastic Leukemia-LymphomaTranscription, GeneticUp-RegulationAntineoplastic AgentsNeoplasm ProteinsPolycomb Repressive Complex 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.